SavedAdd your journal

Journals / Yeni Tıp Dergisi / 2014 / Cilt: 31 - Sayı: 4

New agents used for anticoagulation

Antikoagülasyonda yeni ajanlar

Fatma KEREN
Özlem BALÇIK ŞAHİN
Pages
222–226
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study we will discuss the new oral anticoagulants.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Warfarin which is commonly used for oral anticoagulation has a narrow therapeutic range.
📊
Key Findings & Data:It creates difficulties in following for the patients who are taking long-term treatment.
💡
Conclusion & Impact:In this study we will discuss the new oral anticoagulants.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Warfarin which is commonly used for oral anticoagulation has a narrow therapeutic range. It creates difficulties in following for the patients who are taking long-term treatment. When using oral anticoagulants; the aim is to protect the patient from bleeding and/or thrombosis, and to provide effective anticoagulation. Therefore new molecules with easy use and follow-up and free from drug-food interaction are developed. New agents are inhibitors of factor Xa and IIa (thrombin). In our country, the new oral anticoagulant preparations dabigatran, rivaroxaban and apixaban are still in use. Its endications include primary treatment and secondary prevention of venous thromboembolism, prophylaxis of venous thrombo- embolism after total hip and knee arthroplasty and prevention of stroke and systemic embolism after nonvalvular atrial fibrillation. For now these agents are used cautiously. There is still no treatment options against bleeding complications. Antidotes that are being developed are promising for prevention of bleeding complications. These agents still don’t have enough data for use during pregnancy. In this study we will discuss the new oral anticoagulants.

Özet

Oral antikoagülasyonda s  k kullan  lan varfarinin terapötik aral  ğ  dard  r. Uzun süre tedavi almak zorunda olan hastalar için takip zorlu ğ u olu şturur. Oral antikoagülan kullan  l  rken amaç hastay kanama ve/veya trombozdan korumak ve etkin antikoagülasyon sa ğ lamakt r. Bu nedenle takip ve kullan  m  kolay olan, ilaç-yemek etkile şimi olmayan yeni moleküller geliş tirilmiştir. Yeni ajanlar faktör Xa ve IIa (thrombin) inhibitörleridir. Ülkemizde halen kullan  lan yeni oral antikoagülanlar dabi- gatran, rivaroxaban, apixaban preparatlar d  r. Venöz tromboembolide primer tedavi ve sekonder korumada, total kalça ve diz artroplastisi sonras  venöz trombo- emboli proflaksisinde, nonvalvüler atrial fibrilasyon sonras  inme ve sistemik emboliyi önlemede endikasyonlar  vard  r. Bu ajanlar ş imdilik temkinli kullan  lmak- tad  r. Halen kanama komplikasyonuna karş  tedavi seçenekleri yoktur. Geliş tirilmekte olan antidotlar kanama komplikasyonlar  n  n önleminde ümit vaat etmektedir. Yeterli veri bulunmayan bu ajanlar halen gebelik döneminde kullan  ma uygun de ğ ildir. Bu derlemede yeni oral antikoagülanlardan bahsedilecektir.

🔖

Cite This Article

KEREN, F., ŞAHİN, Ö. B. (2014). New agents used for anticoagulation. Yeni Tıp Dergisi, Cilt: 31 - Sayı: 4, 222–226. https://ajindex.com/articles/338483

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011;154:311
  2. Kearon C, Hirsh J. Changing indications for warfarin therapy. In: Recent Advances in Blood Coagulation. Poller L, Ludlam CA (eds). New York, Churchill Livingstone 1997:141-60
  3. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292–303
  4. Funk DM. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012:460–5
  5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
  6. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342–52
  7. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): a randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721–9
  8. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83
  9. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178–85
  10. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplast 2009;24:1–9
  11. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. 2011, March
  12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
  13. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397–402
  14. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or varfarin